Antibody Discovery and Therapeutic Approval

About 50%

www.antibodysociety.org/antibody-therapeutics-product-data/

Not specified in the text, but can be calculated from the data

<p>From Antibody Discovery till Therapeutic Approval</p> Signup and view all the answers

<p>Rene Hoet</p> Signup and view all the answers

<p>Monospecific antibodies bind to a single target, while bispecific antibodies bind to two targets.</p> Signup and view all the answers

<p>Bispecific antibodies can achieve greater efficacy on a single patho-mechanism and address multiple patho-mechanisms simultaneously.</p> Signup and view all the answers

<p>Tunable stoichiometry allows for the ability to adjust the ratio of binding to the two targets (A and B), such as 1A:1B, 2A:1B, or 2A:2B.</p> Signup and view all the answers

<p>CD20 x CD3 bispecific T cell engagers.</p> Signup and view all the answers

<p>Bispecific antibodies can enable first-in-class therapies by activating two co-receptors/co-factors, enhancing receptor inhibition, or increasing therapeutic window through cell-specific targeting.</p> Signup and view all the answers

<p>Bispecific antibodies can increase therapeutic window through cell-specific targeting, allowing for more precise and effective treatment.</p> Signup and view all the answers

<p>To select antibodies for developability</p> Signup and view all the answers

<p>10^9 CFU</p> Signup and view all the answers

<p>10^27 CFU</p> Signup and view all the answers

<p>Mimicking FVII</p> Signup and view all the answers

<p>Activating γδT cells</p> Signup and view all the answers

<p>Improved developability and high affinity/potency</p> Signup and view all the answers

<p>To explore 1027 diversity and select heavy chain and light chain scaffolds that are most frequently used in humans.</p> Signup and view all the answers

<p>To mimic human diversity in the heavy and light chains.</p> Signup and view all the answers

<p>By incorporating microfluidics technologies for soluble functional screening and 'shuffling' modules in the final antibody format.</p> Signup and view all the answers

<p>To reduce biophysical liabilities and improve the developability of the antibodies.</p> Signup and view all the answers

<p>It enables the generation of highly developable antibodies with a total diversity of 1027 individual modules.</p> Signup and view all the answers

<p>To obtain CDR3-H3 and CDR3-L3 diversity from human donors.</p> Signup and view all the answers

<p>Current limitations of immunotherapy include the ability of tumors to escape immune surveillance by downregulating the immune system. These limitations can be addressed through new approaches to induce immune response, such as targeting 'cold tumors' and combining immunotherapies with other treatments.</p> Signup and view all the answers

<p>gd T-cells have a dual effect of direct tumor lysis and immune response modulation. They also have high frequency and tumor-infiltrating capabilities in many cancers, are not restricted by MHC alleles, and have no correlation with αβ TILs, making them a promising target for immunotherapy.</p> Signup and view all the answers

<p>The current focus of immunotherapy research is on new combinations of immunotherapies, including targeting CTLA-4 and PD-1(PD-L1) for additional cancer indications. The challenge is that only a subset of patients respond to these treatments, and new approaches are needed to induce immune response.</p> Signup and view all the answers

<p>Approved antibodies as inhibitors of immune checkpoint regulators, such as aCTLA-4, aPD1, and aPDL1, have been shown to be effective in treating certain cancers, but there is still a need for new approaches to induce immune response.</p> Signup and view all the answers

<p>gd T-cells differ from αβ T cells in that they have no correlation between αβ TILs and TCR Vγ9Vδ2+ γδ TILs, making them a distinct population of immune cells. This difference has implications for immunotherapy, as gd T-cells may be a promising target for combination therapies.</p> Signup and view all the answers

<p>The prognostic impact of genes and infiltrating immune cells across cancers suggests that the presence of certain immune cells is correlated with favorable clinical outcomes. This has implications for immunotherapy, as targeting these immune cells may improve patient outcomes.</p> Signup and view all the answers